Marketing-authorisation holder · United States
Novo
13 medicines in 1 country, as authorisation holder.
Medicines
Every medicine in the registers under its name, current ones first.
13 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| FIASP1000 units/10ml (100 units/ml) · Solution | Insulin aspart | United States | Marketed | 2017 |
| FIASP FLEXTOUCH300 units/3ml (100 units/ml) · Solution | Insulin aspart | United States | Marketed | 2017 |
| FIASP PENFILL300 units/3ml (100 units/ml) · Solution | Insulin aspart | United States | Marketed | 2017 |
| OZEMPIC1.5mg | 4mg | 9mg · Tablet | Semaglutide | United States | Marketed | 2019 |
| OZEMPIC0.25mg/0.5ml (0.25mg/0.5ml) | 0.5mg/0.5ml (0.5mg/0.5ml) | 1mg/0.5ml (1mg/0.5ml) | 2mg/1.5ml (1.34mg/ml) | 2mg/3ml (0.68mg/ml) | 4mg/3ml (1.34mg/ml) | 8mg/3ml (2.68mg/ml) · Solution | Semaglutide | United States | Marketed | 2017 |
| RIVFLOZA128mg base/0.8ml (eq 160mg base/ml) | 160mg base/ml (eq 160mg base/ml) | 80mg base/0.5ml (eq 160mg base/ml) · Solution | Nedosiran | United States | Marketed | 2023 |
| RYZODEG 70/3090 units/3ml; 210 units/3ml (30 units/ml · Solution | Insulin aspart, Insulin degludec | United States | Not marketed | 2015 |
| SAXENDA18mg/3ml (6mg/ml) · Solution | Liraglutide | United States | Marketed | 2014 |
| TRESIBA1000 units/10ml (100 units/ml) | 300 units/3ml (100 units/ml) | 600 units/3ml (200 units/ml) · Solution | Insulin degludec | United States | Marketed | 2015 |
| WEGOVY1.5mg | 25mg | 4mg | 9mg · Tablet | Semaglutide | United States | Marketed | 2025 |
| WEGOVY0.25mg/0.5ml (0.25mg/0.5ml) | 0.5mg/0.5ml (0.5mg/0.5ml) | 1.7mg/0.75ml (1.7mg/0.75ml) | 1mg/0.5ml (1mg/0.5ml) | 2.4mg/0.75ml (2.4mg/0.75ml) · Solution | Semaglutide | United States | Marketed | 2021 |
| WEGOVY HD7.2mg/0.75ml (7.2mg/0.75ml) · Solution | Semaglutide | United States | Marketed | 2021 |
| XULTOPHY 100/3.6300 units/3ml; 10.8mg/3ml (100 units/ml · Solution | Insulin degludec, Liraglutide | United States | Marketed | 2016 |